Short answer
ARS Pharmaceuticals, Inc. (SPRY) filed an 8-K current report with the SEC on July 17, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Richard Lowenthal resigned from the Board effective July 15, 2026, tied to severance eligibility.
ARS Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Richard Lowenthal resigned from the Board effective July 15, 2026, tied to severance eligibility
- Chief Medical Officer Sarina Tanimoto terminated without cause on July 15, 2026
- Additional prorated 2026 bonus payments: $217,350 to Lowenthal and $111,780 to Tanimoto
- Payments and severance contingent on effective releases of claims by both executives
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ARS Pharmaceuticals, Inc. 8-K filings
Get the next SPRY 8-K as it lands
Follow SPRY for push alerts, or ask the research agent what this filing means.